anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a Chinese herbal medicine for treating haemorrhoids and a preparation method thereof, and relates to a medicine. The preparation method comprises the following steps: by taking stinging shells (involucres) of fagaceae chestnuts as a raw material, crushing; uniformly stirring the medicinal raw material and a solvent of which the quantity is the same as the quantity of the medicinal raw material, moisturizing and standing for 3 hours in an airtight environment; then, placing in a percolating tank; blending with a proper amount of water; placing for 24 hours; starting percolating, and collecting about 90% of the liquid medicine; feeding the collected liquid to the percolating tank filled with the medicinal raw material to be re-percolated; squeezing the liquid dregs to obtain the liquid medicine; mixing the collected liquid; filtering; then, sterilizing the extract liquid and drying at a low temperature to prepare loose powder; and accurately metering, and filling into capsules or blending with a proper amount of an auxiliary material starch, and pressing into 0.5g troche. The stinging shells of chestnuts are cold in nature and tastes sweet and puckery, and have the functions of detoxifying and eliminating swelling. Modern medicine research discovers that the Chinese herbal medicine has the pharmacologic action of preventing bacteria and inflammation and inhibiting ileum peristalsis. Through clinical use, the Chinese herbal medicine is remarkable in effect of treating haemorrhoids. The medicinal material source of the product is wide and easily available; the product is low in cost and good in curative effect, hardly causes side effect, and has a huge development and utilization value.
Disclosed herein are compositions and methods for reducing the growth of hematopoietic malignant cells (e.g., B-cell leukemia cells). The methods involve reducing the growth of hematopoietic malignant cells by contacting hematopoietic malignant cells with GP88 antagonists. GP88 is an 88 KDa autocrine growth factor that promotes the growth of hematopoictic malignant cells. Antagonists to GP88 are provided which inhibit its expression or biological activity. The antagonists include antisense oligonucleotides and antibodies. Also provided are methods for determining if a patient is responding or is responsive to anti-cancer therapy (e.g., glucocorticoid therapy). Increased levels of GP88 in hematopoietic cells indicates a patient is not responding or responsive to anti-cancer therapy.
During Phase 1 (Treatment Phase: 1 cycle; 28 days of treatment), utilizing a rolling 6 design, participants with recurrent or refractory solid tumors will receive escalating doses of lenvatinib in combination with everolimus for determination of the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D). Participants who complete 1 cycle of treatment will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.
PURPOSE:A bathing agent showing improved effect on prevention of allergic dermatosis of bathing people caused by spice and dye contained in bathing agent, by synergistic action, and on suppression of ingravesence of dermatosis, comprising Glycyrrhizae Radix and rice bran as essential components. CONSTITUTION:A bathing agent comprising dried root and STRON of Glycyrrhiza glabra L. var. glandulifera Reg. etc. Herd (=G. glandulifera Waldstein et Kitaibel) and Glycyrrhiaza uralensis Fisch. et DC. of Leguminosae and fermented rice bran as essential components. the dried root of Grycyrrhiza glabar L. var. glandulifera Reg. at Herd, grinding it to give powder or cutting it into pieces, immersing the powder of the pieces in warm water at 40-80 deg.C and is used in the form of a hot water extracted esence obtained by eluting an extracted essence comprising glycyrrhizin in Glycyrrhiza glabra L. var. glandulifera Reg. et Herd as a main component. Rice bran is allowed to stand at 20-60 deg.C for 0.5-2hr, fermented, ground, and used as fermented rice bran. Addition of a ginger further increases preventing effects on allergic dermatosis.
Patients undergo hypofractionated partial breast irradiation daily for 5 days. Patients may then receive 3 additional boost fractions at the discretion of the doctor.
Up to 20 adult subjects will be enrolled at the research center. Atlanta Diabetes Associates (ADA), with at least 15 subjects meeting the eligibility criteria. Eligibility criteria will be assessed at the screening visit and confirmed prior to Visit 2. At Visit 2, subjects will be provided supplies, including the DUO device, and will be trained on insertion. Each subject will wear their own MiniMed 670G insulin system including Guardian sensor (new sensor with transmitter will be provided for the study) and a DUO Extended set. The infusion set in the DUO Extended will be used for insulin infusion and the sensor in the DUO Extended will be blinded with a specific recorder connected to each sensor.

Guardian Sensor (3) and the SMBG measurements will be used for making therapy decisions as approved for the 670G system. Subjects will upload their pump, Contour meter and GS3 sensor data each week, which will be reviewed by an investigator. Subjects will wear the DUO device for a total of four weeks. At Visit 6, subjects will come to the site to have devices uploaded, to return the investigational devices, to have a skin assessment and for labs to be drawn.
Provided is a foam-generating cosmetic sheet which can provide enough effects of blood circulation acceleration, resulting from generation of carbonic acid gas, massage and so on to desired areas on the skin of a user, provides excellent handling sensation and use sensation when used, and has a long-lasting foaming time. The foam-generating cosmetic sheet is a fabric sheet comprising an inner layer and an outer layer. The inner layer includes 1-100 wt% of a cosmetic material including carbonates, organic acid, and a foam stabilizer. The weight of the cosmetic sheet is 40-300 g/m^2. The inner layer preferably comprises: (a) 1-80 wt% of the cosmetic material including carbonates, organic acid, and the foam stabilizer; (b) 20-95 wt% of heat-adhesive fibers with the fineness of 1-4.4 dtex; and (c) 0-60 wt% of cellulose-based pulp. [(a)+(b)+(c)=100 wt%]
Dementia is defined as cognitive impairment associated with loss of autonomy and is usually preceded by a prodromal phase - Mild Cognitive Impairment (MCI) - which represents a highly heterogeneous entity comprising different underlying etiologies, of which Alzheimer's disease (AD) is one of the most prevalent. Several AD biomarkers - including MRI, FDG-PET and CSF measures of amyloid and tau pathology - have been validated as diagnostic (allowing an early and differential diagnosis of AD) and prognostic (predicting progression from MCI to dementia due to AD) tools. In contrast and despite the increasing consensus on their clinical utility, usage of PET markers of amyloid and tau pathology is not yet standard clinical practice. Moreover, while the clinical utility of amyloid-PET has been exhaustively investigated, to date no study has prospectively assessed the clinical utility of tau-PET. Assessing the clinical utility of diagnostic tools is fundamental for clinical practice. This will be the first study assessing the clinical utility of \[18F\]RO948 tau-PET vs. standard of care amyloid-PET, providing unique information to define appropriate diagnostic algorithms
Limited data are available related to overdosage in humans.

Azilsartan medoxomil

Limited data are available related to overdosage in humans. During controlled clinical trials in healthy subjects, once daily doses up to 320 mg of azilsartan medoxomil were administered for 7 days and were well tolerated. In the event of an overdose, supportive therapy should be instituted as dictated by the patient's clinical status. Azilsartan is not dialyzable.

Chlorthalidone

Symptoms of acute overdosage include nausea, weakness, dizziness, and disturbances of electrolyte balance. The oral LD50 of the drug in the mouse and the rat is more than 25,000 mg/kg body weight. The minimum lethal dose (MLD) in humans has not been established. There is no specific antidote, but gastric lavage is recommended, followed by supportive treatment. Where necessary, this may include intravenous dextrose-saline with potassium, administered with caution.
BACKGROUND: Immune-related pneumonitis (irP) is one of the most important immune-related adverse events caused by immune checkpoint inhibitors (ICIs). After corticosteroid therapy irP frequently relapses, which can interfere with cancer therapy. However, risk factors for irP relapse are unknown.
METHODS: This study was a follow-up analysis of a phase II study that evaluated 56 patients with grade ≥ 2 irP treated with oral prednisolone, 1 mg/kg/day, tapered over 6 weeks. Clinical factors including patient characteristics, blood test findings, and response to prednisolone therapy were assessed to identify risk factors for irP relapse using the Fine-Gray test.
RESULTS: Among 56 patients with irP, 22 (39.3%) experienced irP relapse after 6 weeks of prednisolone therapy during the follow-up observation period. Radiographic organising pneumonia (OP) pattern and duration to irP onset ≥ 100 days from ICI initiation were determined to be significant risk factors for irP relapse in a multivariate Fine-Gray test (hazard ratio [HR] = 3.17, 95% CI 1.37-7.32, p = 0.007, and HR = 2.61, 95% CI 1.01-6.74, p = 0.048, respectively). Other patient characteristics, blood test findings, irP severity, and response to prednisolone therapy were not associated with irP relapse.
CONCLUSIONS: In irP patients treated with 6-week prednisolone tapering therapy, OP pattern and duration to irP onset ≥ 100 days were associated with relapse risk. Assessment of the risk factors for irP relapse will be helpful for irP management.
The invention discloses a methacrylic acid-ethyl acrylate copolymer water dispersion enteric material. The invention is characterized in that the material is prepared from the following raw materials in parts by weight: 130-140 parts of methacrylic acid, 150-160 parts of ethyl acrylate, 0.2-1.2 parts of potassium persulfate or ammonium persulfate, 2.1-4.5 parts of sodium lauryl sulfate, 5-7 parts of polysorbate and 650-700 parts of purified water. The invention also discloses a manufacturing method of the methacrylic acid-ethyl acrylate copolymer water dispersion enteric material. The pH value of the methacrylic acid-ethyl acrylate copolymer water dispersion enteric material is 2.0-3.0. The average molecular weight of the methacrylic acid-ethyl acrylate copolymer is 0.25 million or so; and the ratio of the methacrylic acid to the ethyl acrylate in the copolymer is 1:1, wherein the copolymer accounts for 28.5-31.5 wt% of the total methacrylic acid-ethyl acrylate copolymer water dispersion enteric material. The material has the advantages of favorable plasticity and the like, and can easily form a film.
A potato and cistanche-containing life-protecting decoction comprises 13 traditional Chinese medicines such as 30 g of potato, 30 g of herba cistanches, 30 g of oriental waterplantain rhizome and 25 g of fleeceflower root. The main treating symptom of the decoction is characterized in that men or women 16 and older, which are disease-free in bodies, can take the decoction. The effects of the decoction are that lifetime of people can be prolonged, and lifetime can reach 160 years on the basis of 105 years. Firstly, latent disease should be detected and cured, then the decoction is taken to boost immunity, prevent various infectious disease, control increase of cholesterol and prevent cerebrovascular stroke. Formation of sputum stagnation and blood stasis toxicity should be paid attention to, in particular, occurrence of cancer, heart disease, and other serious disease are prevented. In the prescription, six medicines such as the potato and vaccinium bracteatum can largely increase leukocytes in bodies so as to boost immunity, thus achieving an objective of prolonging lifetime.
Purified antibodies that bind to  M. tuberculosis  ERP protein are disclosed. In one embodiment, a purified antibody, which binds specifically with a polypeptide comprising SEQ ID NO: 39 or SEQ ID NO: 41 is provided. In some embodiments the polypeptide has a theoretical molecular weight of about 28 kDa. In other embodiments the polypeptide has an observed molecular weight of about 36 kDa, as determined by denaturing polyacrylamide gel electrophoresis (SDS-PAGE). The purified antibody may be a monoclonal or a polyclonal antibody. Further embodiments provide antibodies that does not bind specifically with  M. leprae  P28 protein. The antibodies of the invention have many uses including the identification of  M. tuberculosis.
BACKGROUND/OBJECTIVE: We evaluated patients with fibromyalgia syndrome (FMS) to determine whether there is a correlation between pain scores based on a 0- to 10-point visual analog scale (VAS) and muscle pressure.
METHODS: One hundred forty-two patients who satisfied the American College of Rheumatology classification criteria for FMS and 38 non-FMS controls comprised the study groups. Muscle pressure was measured in mm Hg using a pressure gauge attached to a no. 22 needle inserted into the midportion of the trapezius muscle. The muscle pressure was then correlated with the VAS pain score of 0 to 10, some with an increment of 0.5. A second muscle pressure was obtained from 19 patients at a subsequent visit, which was compared with their pain scores.
RESULTS: The mean (SD) pain score for 142 patients with FMS was 6.6 (SD, 1.84) on a 0- to 10-point VAS. The mean pain score in the non-FMS subjects was 0.7 (SD, 1.26). The mean muscle pressure in the FMS group was 32.9 (SD, 6.57) mm Hg. The mean muscle pressure in the non-FMS subjects was 10.6 (SD, 3.85) mm Hg. The calculated Pearson correlation coefficient for muscle pressure versus pain score was 0.8312 ( p < 0.0001). This indicates a highly significant association between subjects' muscle pressure and pain scores. For the repeat muscle pressures, the change in muscle pressure was correlated with the change in pain score, and the resulting Pearson correlation coefficient was 0.9255 ( p < 0.0001). These results again indicate a highly significant association between subjects' muscle pressure and pain scores.
CONCLUSION: The results show that increased muscle pressure may be a significant cause of pain in FMS, and the etiology of the pain may have a large peripheral component in addition to a centralized origin of the pain.
Medical record data was extracted from a sexually transmitted infection (STI) clinic in Providence, Rhode Island to characterize trends in Neisseria gonorrhoeae (GC) infection and explore risk factors. Of 16,601 clinical encounters, 6% (n=991) tested GC positive: 5.28 GC case rate (per 100 encounters) in the first two years of data collection (2015-2016) and 7.04 in the last two years (2020-2021). Analysis suggested a single linear trend line over time (p<.05). Overall, in more recent years, patients were older and more like to identify as male, Black, and Hispanic/Latino, as well as to have reported a previous STI, current symptoms, and specific risk behaviors. GC-positive patients in 2020-2021 were older and more like to identify as female and Black compared to 2015-2016. Lower rates of condom use were especially salient among female patients. These findings may reflect GC trends in the community.
The screening phase will involve identifying Caucasian hypertensive patients who are homozygous for the ClC-Ka Gly/Gly83 and the ClC-Ka Arg/Arg 83 allele. All patients will be on background therapy with an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) at least mid range dosing. If patient is not at recommended dose of ACE or ARB they must be titrated up and be stable on a midrange dose of ACEI or ARB for at least 4 weeks before they can be entered into the study. There will be 2 treatment phases. Phase 1 will be up to 4 weeks in duration and will consist of randomization to one table of eplerenone (25 mg) or matching placebo. On week 2 the patient will be up titrated to two tablets of eplerenone (50 mg) or matching placebo, to achieve a target dose of 50 mg of eplerenone. If the patient cannot tolerate two tablets of eplerenone or matching placebo they can be down titrated to one tablet of eplerenone or matching placebo. The target BP on study medication is \< 130/80 mmHg. After the patients have been up titrated to the maximally tolerated dose of study medication, the background hypertension therapy can be adjusted to reach the target BP of \< 130/80 mmHg by the end of week 4. Phase 2 will be 52 weeks in duration to assess the effects of placebo or eplerenone on LV hypertrophy. Serum potassium will be monitored throughout the study, and if necessary, doses of eplerenone will be titrated down as necessary.
The present invention provides compounds useful for inhibiting the ADAM-10 protein, with selectivity versus MMP-1. Such compounds are useful in the in vitro study of the role of ADAM-10 (and its inhibitors) in biological processes. The present invention also comprises pharmaceutical compositions comprising one or more ADAM-10 inhibitors according to the invention in combination with a pharmaceutically acceptable carrier. Such compositions are useful for the treatment of cancer, arthritis, and disease related to angiogenesis. Correspondingly, the invention also comprises methods of treating forms of cancer, arthritis, and diseases related to angiogenesis in which ADAM-10 plays a critical role. The following structural formula may best represent characteristics of the present invention: (see above formula)
Many reasons can cause anemia, decreased RBC production or increased destruction of circulating RBC. The reasons of the former are lake of nutrients, bone marrow disorder, low level tropic hormone, inflammation associated with infectious, inflammatory, or malignant disorders and the latter are intravascular hemolysis or blood loss. Anemia is characterized by the sign of pallor (reduced oxyhemoglobin in skin or mucous membranes), fatigue, lightheadedness, and weakness associated with low hemoglobin.

Iron deficiency anemia (IDA) is mainly resulted from inadequate iron uptake of food, malabsorption of iron and blood loss. Adult female are easy to have IDA compared to male because of menstruation, pregnancy, lactation and low caloric uptake leading to iron deficiency. In Taiwan, cancer-related and chronic kidney disease also lead to insufficient secretion of erythropoietin (EPO). The cost of long-term use EPO and its derivative drugs is high. Besides, drug resistance, risk of tumor growth and cardiovascular disease are all important issues. However, ferrotherapy will induce GI upset, muscle pain and skin hives. Also, iron supplementation can lead to an increase in infectious disease morbidity in areas where bacterial infections or where malaria are common.

Based on the concept of dietetic invigoration, the investigators investigate the Danggui Buxue Tang (PHY606) composed of Angelicae Sinensis Radix and Astragali Radix in the fields of genomics and metabolomics in the healthy people and the patients with anemia. In the meantime, the investigators will explore whether PHY606 activates the immune function, improves anemia and reduces the side effects induced by anemia treatment. Furthermore, the novel metabolites from Angelicae Sinensis Radix and Astragali Radix will be tested from clinic back to the bench including immunological potentiation and hematopoietic function. According to the TCM theory, the investigators integrate with modern medicine and molecular biotechnology to investigate anemia and hope to provide the evidence base for clinical application.
Trazodone hydrochloride tablets, USP are available in the following strengths:

Trazodone hydrochloride tablets USP, 50 mg are white to off-white, round-shape, biconvex beveled tablets, bisect on one side and plain on other side. The bisected side of tablet is debossed with '8' on upper side of bisect and '05' on lower side of bisect.

Trazodone hydrochloride tablets USP, 100 mg are white to off-white, round-shape, biconvex beveled tablets, bisect on one side and plain on other side. The bisected side of tablet is debossed with '8' on upper side of bisect and '06' on lower side of bisect.

Trazodone hydrochloride tablets USP, 150 mg are white to off-white, oval-shape, flat faced beveled tablets having one full bisect and two trisect notches on one side and two trisects on other side. The full bisected side of tablet is debossed with '8' on one side of bisect and '07' on other bisect segments.

Trazodone hydrochloride tablets USP, 300 mg are white to off-white, oval-shape, flat faced beveled tablets having one full bisect and two trisect notches on one side and two trisects on other side. The full bisected side of tablet is debossed with '8' on one side of bisect and '08' on other bisect segment.
Varenicline binds with high affinity and selectivity at α4β2 neuronal nicotinic acetylcholine receptors. The efficacy of varenicline in smoking cessation is believed to be the result of varenicline's activity at α4β2 sub-type of the nicotinic receptor where its binding produces agonist activity, while simultaneously preventing nicotine binding to these receptors.

Electrophysiology studies in vitro and neurochemical studies in vivo have shown that varenicline binds to α4β2 neuronal nicotinic acetylcholine receptors and stimulates receptor-mediated activity, but at a significantly lower level than nicotine. Varenicline blocks the ability of nicotine to activate α4β2 receptors and thus to stimulate the central nervous mesolimbic dopamine system, believed to be the neuronal mechanism underlying reinforcement and reward experienced upon smoking. Varenicline is highly selective and binds more potently to α4β2 receptors than to other common nicotinic receptors (> 500-fold α3β4, > 3,500-fold α7, > 20,000-fold α1βγδ) or to non- nicotinic receptors and transporters (> 2,000-fold). Varenicline also binds with moderate affinity (Ki=350 nM) to the 5-HT3 receptor.
The WAT group will receive a 3-month WAT-based exercise training programme, which includes 12 weekly exercise training sessions (an hour each) in addition to 2 face-to-face sessions followed by weekly to monthly telephone sessions offering support on dealing with technical issues and BCTs (7 session in total). The WAT group will be left to use the WAT on their own for 3 months during the follow-up period.
The shared decision aid (SDA) includes factual information about the World Health Organization pain ladder, the 0-10 numeric rating score pain scale, pharmacologic pain management options, opioid medication benefits and risks and predicted post-discharge opioid requirements based on previous modeling in total knee arthroplasty patients. Subjects in the decision aid group will view the decision aid and have the opportunity to participate in shared decision-making for their discharge opioid prescriptions.